NA
PMVP icon

Nordwand Advisors’s PMV Pharmaceuticals PMVP Stock Holding History

Nordwand Advisors’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,000
Closed -$2.98K – 134
2024
Q3 		$2.98K Hold
2,000
– – ﹤0.01% 110
2024
Q2 		$3.24K Buy
+2,000
New +$3.61K ﹤0.01% 133

Other funds holding PMVP

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Nordwand Advisors's PMVP Position: Q4 2024 in Review

Nordwand Advisors sold out of PMV Pharmaceuticals (PMVP) in Q4 2024, closing a stake of 2,000 shares — an estimated $2.98K sold.

Nordwand Advisors first reported a position in PMVP in Q2 2024 and held it in 2 quarters. The position peaked at $3.24K in Q2 2024. 70 funds tracked by Wall St. Rank hold PMVP as of Q4 2024.

  • Nordwand Advisors reported no remaining PMV Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Nordwand Advisors sold 2,000 PMV Pharmaceuticals shares in Q4 2024, an estimated $2.98K.
  • Nordwand Advisors first reported a position in PMV Pharmaceuticals in Q2 2024 and held it in 2 quarters.
  • Nordwand Advisors's PMV Pharmaceuticals position peaked at $3.24K in Q2 2024.
  • 70 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q4 2024.

Based on Nordwand Advisors's 13F filing for Q4 2024, filed 7 Feb 2025.